ASLAN Pharmaceuticals Return on Equity

ASLAN Pharmaceuticals (ASLN) currently reports a ROE of 194.97%. That is above the Healthcare sector average of 29.39%. Use the charts on this page to explore ASLAN Pharmaceuticals's ROE history and peer comparisons.

ASLAN Pharmaceuticals's ROE of 194.97% is higher than the Healthcare sector average of 29.39%. That is roughly 563.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but ASLAN Pharmaceuticals's current 194.97% should be judged against Healthcare norms (sector average: 29.39%) and against ASLN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 194.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for ASLAN Pharmaceuticals, and consider following ASLN for alerts when major investors trade the stock.

ASLAN Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 194.97% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ASLN with unrelated industries.